|
|
Volumn 12, Issue 11, 2013, Pages 825-
|
|
Metabolic disorders: FGF21 analogue shows promise in the clinic
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADIPONECTIN;
ANTIDIABETIC AGENT;
ANTIOBESITY AGENT;
CHOLESTEROL;
FIBROBLAST GROWTH FACTOR 21;
FIBROBLAST GROWTH FACTOR 21 DERIVATIVE;
HIGH DENSITY LIPOPROTEIN;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
INSULIN;
LOW DENSITY LIPOPROTEIN;
LY 2405319;
METFORMIN;
PLACEBO;
TRIACYLGLYCEROL;
UNCLASSIFIED DRUG;
ANTIDIABETIC ACTIVITY;
CHOLESTEROL BLOOD LEVEL;
COMORBIDITY;
DRUG MEGADOSE;
DRUG SAFETY;
DRUG TOLERABILITY;
DYSLIPIDEMIA;
ENERGY EXPENDITURE;
ENERGY METABOLISM;
HUMAN;
HYPERSENSITIVITY;
INJECTION SITE REACTION;
INSULIN BLOOD LEVEL;
INSULIN RESISTANCE;
INSULIN SENSITIVITY;
LIPID METABOLISM;
LIPOLYSIS;
LIPOPROTEIN BLOOD LEVEL;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NONHUMAN;
NOTE;
OBESITY;
PRIORITY JOURNAL;
PROTEIN FUNCTION;
PROTEIN SECRETION;
RASH;
TRIACYLGLYCEROL BLOOD LEVEL;
WEIGHT CHANGE;
DIABETES MELLITUS, TYPE 2;
FEMALE;
FIBROBLAST GROWTH FACTORS;
HUMANS;
MALE;
OBESITY;
|
|
EID: 84887067451
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4157 Document Type: Note |
|
Times cited : (3)
|
|
References (1)
|
